1. Scrip
  2. >>Business
  3. >>Deals

In Merger Plot Twist, BMS Needs A Buyer For Celgene's Otezla, Raising New Questions

 
• By Jessica Merrill

Bristol-Myers will have to divest Celgene's blockbuster psoriasis pill to address concerns raised by the US FTC related to the merger. The news raised questions about whether FTC is giving more scrutiny to pipeline overlap.

Top view of a woman reading a book. - Image
A new chapter unfolds in the Bristol/Celgene merger • Source: Shutterstock

Bristol-Myers Squibb Co. is seeking a buyer for Celgene Corp.'s blockbuster psoriasis pill Otezla (apremilast) to address concerns by the US Federal Trade Commission around the planned merger related to competition in psoriasis. The news surprised some investors given that BMS and Celgene don't currently have a significant amount of overlap in the immunology space, and while Otezla was not a main driver of the merger, it is still a significant revenue-generating growth driver.

Otezla is approved for the treatment of moderate-to-severe plaque psoriasis and psoriatic arthritis and generated $1.61bn in 2018, on year-over-year...

More from Deals

Nicox Plots US Submission After Another Phase III Glaucoma Win

 
• By Kevin Grogan

The France-headquartered firm’s eye drop has demonstrated efficacy in a second pivotal trial.

Jazz Seeks Potential Expansion Of Epilepsy Franchise With Saniona Deal

 
• By Mandy Jackson

Deal Snapshot: Jazz, which sells Epidiolex for rare seizure disorders, will pay $42.5m up front to take over development of Saniona’s preclinical Kv7.2/Kv7.3 activator SAN2355 for epilepsy.

Glenmark Fortifying Branded Play, Shifts Focus To High Margin Products

 
• By Anju Ghangurde

Glenmark signals thrust on high margin products, while exiting tail end brands as part of efforts to emerge as a branded company. In-licensed assets like Brukinsa and Tevimbra are seen as pivotal to driving growth alongside.

China-Originated Assets Lead Global GLP-1 Deals

 
• By Xu Hu

The total value of deals for GLP-1-associated assets so far this year is already double that of the previous two years combined, with China-originated molecules accounting for a substantial majority. Scrip takes a look at some of the key factors behind this activity.

More from Business

Celldex Bullish On Barzolvolimab Despite Study Miss

 
• By Kevin Grogan

All eyes on chronic urticaria after eosinophilic esophagitis disappointment.

Glenmark Fortifying Branded Play, Shifts Focus To High Margin Products

 
• By Anju Ghangurde

Glenmark signals thrust on high margin products, while exiting tail end brands as part of efforts to emerge as a branded company. In-licensed assets like Brukinsa and Tevimbra are seen as pivotal to driving growth alongside.

China-Originated Assets Lead Global GLP-1 Deals

 
• By Xu Hu

The total value of deals for GLP-1-associated assets so far this year is already double that of the previous two years combined, with China-originated molecules accounting for a substantial majority. Scrip takes a look at some of the key factors behind this activity.